PLoS ONE (Jan 2023)

Gene and pathway based burden analyses in familial lymphoid cancer cases: Rare variants in immune pathway genes.

  • Sneha Ralli,
  • Samantha J Jones,
  • Stephen Leach,
  • Henry T Lynch,
  • Angela R Brooks-Wilson

DOI
https://doi.org/10.1371/journal.pone.0287602
Journal volume & issue
Vol. 18, no. 6
p. e0287602

Abstract

Read online

Genome-wide association studies have revealed common genetic variants with small effect sizes associated with diverse lymphoid cancers. Family studies have uncovered rare variants with high effect sizes. However, these variants explain only a portion of the heritability of these cancers. Some of the missing heritability may be attributable to rare variants with small effect sizes. We aim to identify rare germline variants associated with familial lymphoid cancers using exome sequencing. One case per family was selected from 39 lymphoid cancer families based on early onset of disease or rarity of subtype. Control data was from Non-Finnish Europeans in gnomAD exomes (N = 56,885) or ExAC (N = 33,370). Gene and pathway-based burden tests for rare variants were performed using TRAPD. Five putatively pathogenic germline variants were found in four genes: INTU, PEX7, EHHADH, and ASXL1. Pathway-based association tests identified the innate and adaptive immune systems, peroxisomal pathway and olfactory receptor pathway as associated with lymphoid cancers in familial cases. Our results suggest that rare inherited defects in the genes involved in immune system and peroxisomal pathway may predispose individuals to lymphoid cancers.